Lebensqualität von Patienten mit Prostatakarzinom unter Androgendeprivation mit GnRH-Analoga

Eisenhardt, Andreas; Schneider, Tim; Scheithe, Karl; Colling, C.; Heidenreich, Axel

doi:10.1007/s00120-015-3989-7

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, initiation of triptorelin six-monthly in newly diagnosed LHRHa-naïve patients (newly initiated group) provided significant and sustained PSA control over 12 months. In both groups, six-monthly triptorelin was well tolerated with reported AEs consistent with previous trials [ 10 , 14 – 18 ].…”

Section: Discussionsupporting

confidence: 79%

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Cornford

Jefferson

Cole³

et al. 2018

Oncol Ther

View full text Add to dashboard Cite

Introduction Luteinising hormone-releasing hormone agonist (LHRHa) injections are currently used in the treatment of advanced prostate cancer, but the frequency of injections may represent a burden to patients and healthcare services. The aim of this study was to collect real-world evidence about clinical and practical outcomes for patients with prostate cancer initiating six-monthly triptorelin, or switching from shorter-acting formulations to six-monthly triptorelin, in hospitals in the DEcapeptyl SERVice Evaluation project. Methods Up to 2 years of data were collected retrospectively by physicians from records of 88 patients receiving six-monthly triptorelin at three centres. The primary outcome measure was the change in the number of patient–healthcare interactions (patient reviews, prostate-specific antigen (PSA) tests, and LHRHa injections) over a 24-month treatment period. Results This analysis included 47 patients newly initiated on six-monthly triptorelin and 41 who received 12 months of a one- or three-monthly LHRHa before switching to six-monthly triptorelin. After switching to six-monthly triptorelin, there was a statistically significant reduction in patient reviews (46.8%), injections (46.8%), and PSA tests (26.6%; all P < 0.0001). The total number of patient–healthcare interactions was significantly reduced (41.5%; P < 0.0001). Based upon cost of these interactions only, the cost reduction of switching to six-monthly triptorelin was £10,214.85 (£249.14 per patient) over 12 months. At 12 months, median PSA was 1.30 ng/mL (23.50 ng/mL at diagnosis) for newly treated patients and 0.24 ng/mL (0.35 ng/mL at switch) for patients who had switched treatment. No safety issues were identified. Conclusion Switching from one- or three-monthly LHRHa to six-monthly triptorelin significantly reduced patient–healthcare interactions and associated costs while maintaining PSA control over a 12-month treatment period. This not only translates into healthcare savings but may release men from the restriction of repeated healthcare interactions and thus improve the overall patient experience as the population of long-term prostate cancer survivors continues to increase. Funding Ipsen Limited.

show abstract

Section: Discussionsupporting

confidence: 79%

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Cornford

Jefferson

Cole³

et al. 2018

Oncol Ther

View full text Add to dashboard Cite

show abstract

“…Studies of sustained-release formulations of triptorelin during routine clinical practice also demonstrate improvements in some aspects of health-related quality of life (HRQoL) and satisfaction in patients [ 52 , 53 , 55 – 58 ]. In an observational study of everyday practice in France, 1438 patients initiating treatment with triptorelin 3- or 6-month formulations for prostate cancer were evaluated for reasons for prescription and patient preference.…”

Section: Triptorelin As Adtmentioning

confidence: 99%

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

Merseburger

Hupe

2016

Adv Ther

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Sustained-release 1-, 3- and 6-month formulations of triptorelin, administered intramuscularly or subcutaneously, have been developed to provide improved flexibility and convenience for the patient. Head-to-head studies of GnRH agonists are lacking in the field of prostate cancer. Despite the inevitable progression to castration-resistant prostate cancer (CRPC) in most patients receiving ADT, monitoring of testosterone levels needs to improve in routine practice and physicians should not overlook the benefits of continued ADT in their patients when introducing one of the various new treatment options for CRPC. For improved survival outcomes, there remains a need to tailor ADT treatment regimens, novel hormonal agents and chemotherapy according to the individual patient with advanced prostate cancer.

show abstract

Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU

McKeage

Lyseng‐Williamson

2017

Drugs Ther Perspect

View full text Add to dashboard Cite

Lebensqualität von Patienten mit Prostatakarzinom unter Androgendeprivation mit GnRH-Analoga

Cited by 5 publications

References 17 publications

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer

Triptorelin 3- and 6-month sustained-release formulations in locally advanced or metastatic prostate cancer: a profile of their use in the EU

Contact Info

Product

Resources

About